Overview

This trial is active, not recruiting.

Condition cocaine use
Treatments l-thp (l-tetrahydropalmatine), placebo
Phase phase 1
Sponsor University of Maryland
Collaborator National Institute on Drug Abuse (NIDA)
Start date October 2012
End date June 2017
Trial size 40 participants
Trial identifier NCT01631383, 1DP1DA031401-01, HP-00051290

Summary

This study will test the safety and pharmacokinetic profile of l-THP with cocaine exposure in people who have a history of cocaine use. The subject will be admitted to the Brief Stay Unit (BSU), an inpatient facility at the Maryland Psychiatric Research Center, used for short term drug abuse or clinical trial studies. The participant will stay for 4 nights and 5 days. He/she will be randomized to either placebo or l-THP for three days. On the morning of Day 4, the subject will receive one cocaine dose (40 mg intranasal) and have testing for pharmacokinetic parameters for the following 10 hours. The subject will stay over one more night and will be discharged the following day. Approximately 40 subjects will be randomized to enroll the target sample of 30 (N=15 placebo, N=15 l-THP). In summary, each subject will come for a screening visit(s), then a 5-day, 4-night stay on a secure research unit. After cocaine administration day, the participant will stay overnight for one more day of observation and to permit substantial l-THP elimination from the body. The following morning we will get one additional blood specimen for l-THP (Day 5 at 24 hours after last dose (7:30 am); then the participant will be discharged. A visit with blood collection on Day 6 at 55 hours after last dose (2:30 pm) will be scheduled. A final follow-up visit will be scheduled 4-7 days after unit discharge to ensure no persisting side effects.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Arm
(Placebo Comparator)
placebo
Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
(Active Comparator)
l-thp (l-tetrahydropalmatine) l-tetrahydropalmatine
Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).

Primary Outcomes

Measure
Peak heart rate after cocaine administration during treatment with l-THP or placebo.
time frame: -10 (min), 5, 20, 35, 50, 65, 80, 95, 2.5 (hr), 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9 10 hr
Peak blood pressure after cocaine administration during treatment with l-THP or placebo
time frame: -10 (min), 5, 20, 35, 50, 65, 80, 95, 2.5 (hr), 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9 10 hr
Peak cocaine plasma concentration after acute cocaine dose during treatment with l-THP
time frame: 0,1,20,30,40,50,60,70,80,90, 100, 110 (min), 2 (hr), 2.5, 3, 3.5, 4, 5, 6 hr

Secondary Outcomes

Measure
Reported side effects of l-THP vs placebo during 3 day dosing
time frame: 3 days
Safety (laboratory measures) of l-THP vs. placebo during 3 day dosing
time frame: 3 Days
Extrapyramidal Side effects of l-THP vs. placebo during 3 days of dosing
time frame: 3 Days
Psychological Side Effects of l-THP vs. placebo during 3 days of dosing
time frame: 3 Days
Craving for cocaine during treatment with l-THP or placebo
time frame: 3Days

Eligibility Criteria

Male or female participants from 18 years up to 50 years old.

Inclusion/Exclusion Criteria: Inclusion criteria: 1. men or non-pregnant/non-nursing women between the ages of 18 and 50 years old 2. self reported history of cocaine use (intranasal, IV or smoked) averaging at least twice monthly for at least one month over the prior year 3. self- reported use at least one use in the past six months of a cocaine dose equivalent to 40 mg intranasal or 15 mg smoked or intravenous, based on participant's best estimate of weight and/or street price of amount ingested and a 4. positive urine drug test for cocaine use at least once in past 1 year 5. HIV seronegative 6. hepatitis C seronegative 7. EKG without clinically significant abnormality 8. normal blood pressure (systolic: 90-140 mmHg; diastolic: 50-90 mmHg) and resting heart rate (60-90 bpm) 9. within 20% of ideal body weight, based on BJ Devine formula (1974) (men: 50 + 2.3 kg per inch over 5 feet, women: 45.5 + 2.3 kg per inch over 5 feet) 10. ability to adhere to the study restrictions and examination schedule 11. Women with reproductive potential must agree to the use of one of the following birth control methods (condom with spermicide, diaphragm, or intrauterine device) during the study and for 2 weeks after study conclusion. Exclusion criteria: 1. participation in any investigational drug trial or clinical drug trial within 45 days before study entry 2. donation or loss of greater than one pint of blood within 60 days of study entry 3. history of clinically significant adverse reaction or hypersensitivity to any study drug, 4. inability to communicate or co-operate with the investigators 5. treatment-seeking for cocaine abuse/dependence 6. taking any concurrent prescription, over the counter medications, or dietary/nutritional/herbal supplement (such as St. John's wort or grapefruit juice, but not including standard vitamin or mineral supplements) within 14 days prior to initial dosing. 7. current clinically significant medical problems that might interfere with safe study participation. This includes pheochromocytoma, untreated hyperthyroidism, dehydration, fever, coronary artery disease, uncorrected congenital heart defect, seizures, electrolyte imbalance, uncontrolled diabetes mellitus, porphyria variegate, superventricular tachycardia, atrial fibrillation, cardiomyopathy, uncontrolled hypertension,. 8. Current Axis I psychiatric disorder (except nicotine dependence, cocaine abuse/dependence, or simple phobia). Nicotine does not alter physiologic response to cocaine (Kouri et al 2001) 9. Positive for illicit drugs other than cocaine or marijuana on urine drug screen 10. Score below 10/12 on the Evaluation to Sign Consent (ESC)

Additional Information

Official title Pharmacokinetic and Safety Evaluation of L-tetrahydropalmatine (l-THP) With Cocaine Exposure in People With a History of Cocaine Use
Principal investigator Deanna L. Kelly, Pharm.D., BCPP
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by University of Maryland.